- Details
- Zachary Klaassen and Luke Nordquist discuss TheranosticTrials.org, a comprehensive global website dedicated to theranostic education and clinical trial information. Dr. Nordquist explains how the platform has expanded from initially covering 150 trials across 12 cancer types to now featuring over 600 trials for 35 different cancers. The website serves as an educational resource for patients, physi...
|
- Details
- Zachary Klaassen and Luke Nordquist discuss the CLARIFY trial, which evaluates a novel Copper-64 SAR-bisPSMA PET imaging technique for high-risk prostate cancer patients before surgery. Dr. Nordquist explains the trial's focus on patients with aggressive disease features who are scheduled for surgery within 90 days, highlighting the advantage of Copper-64's longer half-life which allows for imagin...
|
- Details
- Oliver Sartor and Wolfgang Fendler explore the evolving role of PSMA PET imaging in assessing treatment response and progression in prostate cancer. Dr. Fendler outlines two key assessment approaches: the PPP criteria for early-stage disease focusing on lesion numbers, and the RECIP criteria for advanced disease examining tumor volume changes. The conversation highlights how PSMA PET findings corr...
|
- Details
- Michael Hofman discusses the development of new criteria for evaluating prostate cancer progression using PSMA PET-CT scans. This work aims to standardize response evaluation and potentially replace the current PCWG3 guidelines that rely on CT and bone scans. Using data from the PRINCE trial, Dr. Hofman's team demonstrates high inter-reader agreement for the new criteria, with almost perfect agree...
|
- Details
- Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure, which potentially offer improved imaging characteristics over existing PSMA agents. Dr. Emmett highlights early study results showing higher intensity uptake in cancer cells compared to gallium PSMA-11. The conversation...
|
- Details
- Neal Shore discusses a new 64Cu-SAR-bisPSMA PET diagnostic agent for prostate cancer imaging with Phillip Koo. Dr. Shore highlights the unique features of this compound, including its bivalent structure and longer half-life compared to existing PSMA PET agents. He explains how these characteristics allow for next-day imaging, potentially improving detection rates and clinical flexibility. Dr. Shor...
|
- Details
- Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. He emphasizes the distinction between radiological progression and treatment failure, noting the lack of validated parameters...
|
- Details
- Zachary Klaassen and Phillip Koo discuss the results from the COBRA study, focusing on the innovative 64Cu-SAR-bisPSMA PET imaging presented at ASCO 2024. Dr. Koo explains that this new imaging agent has unique dual binding sites and advanced chelator technology, enhancing its attachment to prostate cancer cells and increasing the detection rate. The COBRA trial reveals that imaging performed the...
|
- Details
- Alicia Morgans discusses advances in prostate cancer imaging and theranostics with Michael Hofman. Dr. Hofman emphasizes the growing variety of PSMA ligands for PET-CT imaging and treatment, comparing their subtle differences and implications for clinical practice. He notes that while ligands like Gallium PSMA-11 and DCFPyL are similar and FDA-approved, others like PSMA-1007, although widely used...
|
- Details
- Phillip Koo and Neal Shore discuss the COBRA trial, which investigates the use of 64Cu-SAR-bisPSMA PET imaging in prostate cancer patients with biochemical recurrence (BCR). Dr. Shore, the lead principal investigator, introduces Clarity, an Australian company developing Copper-64-based radiopharmaceuticals. He explains the advantages of Copper-64, such as its long half-life and bivalent structure,...
|
